Sydnexis

Executive Summary

Sydnexis is a clinical-stage biotechnology company focused on developing a novel treatment for pediatric progressive myopia (PPM), the leading cause of vision loss in children. Current standard of care—corrective lenses—addresses symptoms but does not halt disease progression, leaving a significant unmet need for disease-modifying therapies, especially in younger children. Sydnexis’ lead candidate is a proprietary low-dose atropine formulation designed to slow myopia progression with an improved safety profile. The company is currently conducting a Phase 3 clinical trial evaluating this therapy, positioning it as a potential first-in-class treatment for PPM. If successful, Sydnexis could capture a large market opportunity given the high prevalence of myopia in children and the lack of approved pharmacologic options. The company’s focus on a well-validated mechanism with optimized dosing and delivery may reduce side effects such as photophobia and accommodative dysfunction, enhancing compliance and efficacy. With Phase 3 data anticipated in the near term, Sydnexis represents a compelling investment in the ophthalmology space, addressing a critical gap in pediatric eye care.

Upcoming Catalysts (preview)

• Q2 2026Phase 3 top-line data readout60% success
• Q4 2026New Drug Application (NDA) submission50% success
• Q3 2026Strategic partnership for commercialization40% success